Annovis Announces New Publication in a Peer-Reviewed Journal
May 21, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
May 13, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
May 09, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
May 06, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
April 29, 2024 10:10 ET
|
Annovis Bio Inc.
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is...
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
April 02, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
April 01, 2024 08:00 ET
|
Annovis Bio Inc.
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company...
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
March 20, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced...
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
February 27, 2024 08:00 ET
|
Annovis Bio Inc.
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
February 14, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...